Advances in the Diagnosis and Individualized Treatment of MDS: Molecular Testing, Emerging Therapies, and AML Commonalities

Release Date: March 31, 2023
Expiration Date: March 31, 2024
Time to Complete Activity: 0.5 hour



Guillermo Garcia-Manero, MD
McCredie Professor of Medicine
Vice Chair, Department of Leukemia
Chief, Section of Myelodysplastic Syndromes
Deputy Chair, Translational Research
The University of Texas MD Anderson Cancer Center
Houston, TX

Daniel A. Pollyea, MD, MS
Professor of Medicine, Division of Hematology
Clinical Director of Leukemia Services
Robert H. Allen, MD Endowed Chair in Hematology Research
University of Colorado School of Medicine
Aurora, CO

Target Audience 

This activity has been designed to address the educational needs of hematology/oncology physicians, pathologists, pharmacists, and oncology advanced practitioners. It may also benefit oncology nurses and other healthcare professionals who manage patients with myelodysplastic syndrome (MDS) and/or acute myeloid leukemia (AML).

Educational Provider

This activity is jointly provided by Paradigm Medical Communications, LLC and Educational Review Systems, Inc. 

In collaboration with The MDS Foundation. 


Supporter Acknowledgment 

This activity is supported by an independent educational grant from Gilead Sciences, Inc.    

Program Overview 

The management of MDS is evolving, with the publication and adoption of the International Prognostic Scoring System-Molecular (IPSS-M), which now includes molecular testing results for prognostication. In addition, the treatment of MDS is poised to change as well, as several emerging agents have demonstrated promising results in early phase trials and are now being evaluated in phase 3 studies. Given this, new questions have arisen about risk stratification and treatment selection now and in the future for higher-risk MDS. In addition, the high similarity between TP53-mutated MDS and AML suggests that they are a single entity that can be treated similarly. This interactive infographic will engage learners in a multimedia journey about the latest updates on the management of higher-risk MDS and the overlap between MDS and AML with mutated TP53.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply molecular testing results into prognostication of MDS using the IPSS-M system as it relates to treatment planning 
  • Outline the emerging therapies in the late stages of development for the treatment of higher-risk MDS, including mechanisms of action, clinical trials, and any efficacy and safety data 
  • Describe the overlap between higher-risk MDS and AML, particularly as it relates to the treatment of TP53-mutated disease

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Paradigm Medical Communications, LLC and Educational Review Systems, Inc. Paradigm Medical Communications, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation Statement

Paradigm Medical Communications, LLC designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Education 

PAs may claim a maximum of 0.50 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education 

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Pharmacist Accreditation and Designation Statement

Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 0.5 contact hour (0.05 CEU) submitted to CPE Monitor as early as 14 days after completion and no later than 60 days after completion. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.

UAN # 0761-9999-23-017-H01-P

This is a knowledge-based activity.

Hardware/Software Requirements

This accredited CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.

Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+

PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here:


Technical Support:

If you have any technical problems or playback issues, email us at

Instructions for Participation

To receive a certificate of participation, participants must:

  • Follow instructions to register or log in with your professional information and complete the preassessment
  • View the online activity in its entirety
  • Complete and submit the online postassessment and evaluation. You must answer 70% of the postassessment questions correctly to earn credit. You will have unlimited opportunities to successfully complete the postassessment

A certificate of participation will be available for download/printing immediately following your successful completion of the postassessment and evaluation.

For questions regarding CME credit, contact the Paradigm CME Department at

There are no fees for participating in this activity.


Disclosure of Relevant Financial Relationships

In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, Paradigm requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months.

All relevant relationships are identified and mitigated according to Paradigm policy prior to individuals assuming their roles, and are disclosed prior to learners’ engagement in the activity. Paradigm is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The content of this activity was independently reviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated. 

Guillermo Garcia-Manero, MD
Has no relevant financial relationships with ineligible companies to disclose.

Daniel A. Pollyea, MD, MS
Advisor: AbbVie Inc.; Aprea Therapeutics; Aptevo Therapeutics; Arcellx; Astellas Pharma US, Inc; AstraZeneca; BeiGene Inc.; BerGenBio ASA; Bristol-Myers Squibb Company; Daiichi Sankyo Company, Limited; Foghorn Therapeutics; Genentech, Inc.; Gilead Sciences, Inc.; HiberCell Inc; ImmunoGen, Inc.; Jazz Pharmaceuticals, Inc; Karyopharm; Kura Oncology, Inc; Link Pharma Chem Ltd; Magenta Therapeutics; Medivir AB; Novartis AG; Qihan Biotech Co, Ltd; Ryvu Therapeutics; Syndax; Syros Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Ltd; Zentalis Pharmaceuticals
Research Funding: AbbVie Inc.; Bristol-Myers Squibb Company; Karyopharm; Teva Pharmaceutical Industries Ltd.

Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies to disclose.

Educational Review Systems, Inc staff members have no relevant financial relationships with ineligible companies to disclose.

Independent peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.


This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC. 


Terms of Use and Privacy Policy

The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.

Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.

Contact Us

If you have any questions or comments, please email us at

© 2023 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.